Neratinib sustained-release implant for treating solid tumor

A sustained release implant includes 0.1%-50% (w/w) nilotinib, 50-99% sustained release excipients and 0-15% sustained release moderator. Sustained release excipients are mainly one or combination of poly (L-lactide-co-ethyl phosphate), poly (L-lactide-co- phosphoric acid propyl), polylactic acid, the copolymer of polylactic acid and hydroxyacetic acid and polifeprosan; sustained release moderator is one or combination of mannitol, sorbic alcohol and chondroitin; sustained release implant applied in local tumor can slowly release nilotinib onto local tumor, thus maintaining effective drug concentration of local tumor as well as significantly reducing overall toxic reaction; the invention not only reduces overall toxic reaction of nilotinib, but also selectively improves drug concentration in local tumor, enhancing the therapeutic effects of non-operative therapy such as chemotherapy drugs and radiotherapy. The implant can be used for treating solid tumors including lung cancer, esophageal carcinoma, gastric cancer, liver cancer, breast cancer, ovarian cancer, prostatic carcinoma, pancreatic cancer, bladder carcinoma, cerebroma, and colorectal cancer.